VA
ATYR

VR Adviser’s aTyr Pharma ATYR Stock Holding History

VR Adviser’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,171,436
Closed -$2.57M – 29
2022
Q4 		$2.57M Sell
1,171,436
-227,453
-16% -$536K 0.43% 26
2022
Q3 		$4.2M Hold
1,398,889
– – 0.65% 28
2022
Q2 		$3.96M Hold
1,398,889
– – 0.78% 24
2022
Q1 		$7.48M Sell
1,398,889
-166,111
-11% -$941K 1.21% 20
2021
Q4 		$11.7M Hold
1,565,000
– – 1.6% 19
2021
Q3 		$14.2M Buy
+1,565,000
New +$9.36M 1.83% 18

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser's ATYR Position: Q1 2023 in Review

VR Adviser sold out of aTyr Pharma (ATYR) in Q1 2023, closing a stake of 1,171,436 shares — an estimated $2.57M sold.

VR Adviser first reported a position in ATYR in Q3 2021 and held it in 6 quarters. The position peaked at $14.2M in Q3 2021. 37 funds tracked by Wall St. Rank hold ATYR as of Q1 2023.

  • VR Adviser reported no remaining aTyr Pharma position as of Q1 2023 after selling out during the quarter.
  • VR Adviser sold 1,171,436 aTyr Pharma shares in Q1 2023, an estimated $2.57M.
  • VR Adviser first reported a position in aTyr Pharma in Q3 2021 and held it in 6 quarters.
  • VR Adviser's aTyr Pharma position peaked at $14.2M in Q3 2021.
  • 37 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2023.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.